Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies

In 2007, Omnitrope ® was the first biosimilar recombinant human growth hormone (rhGH) to be approved in Sweden for treatment in adults and children. Over 10 years’ safety and effectiveness data for biosimilar r...

Source: BMC Endocrine Disorders - April 29, 2020 Category: Endocrinology Authors: Elena Lundberg, Berit Kristr öm, Hichem Zouater, Anna Deleskog and Charlotte Höybye Tags: Research article Source Type: research